Phenotypic and functional alterations in primate lymphoid organs following SIV and HIV infection. NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Phenotypic and functional alterations in primate lymphoid organs following SIV and HIV infection.

Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:44 (abstract no. 28). Unique Identifier : AIDSLINE PRIM8/900028
Rosenberg YJ; White BD; Lewis M; Mosca J; Papermaster SF; Kersey K; Eddy GA; Burke DS; Henry M. Jackson Foundation, Rockville, MD


Abstract: The aim of the present study is to examine the susceptibility of lymphoid organs to infection with HIV and SIV and to compare alterations in the phenotypic and functional properties of those T cell subsets which may be differentially affected by infection. The anti-CD45RA MAb ALB11 delineates human and monkey T cells into three distinct subsets: CD45RAlo memory cells, CD45RAmed antigen naive cells and a third CD45RAhi partially activated 'anergic' pool. This MAb has been used in conjunction with MAbs to other activation markers to both define the subsets present in thymus, spleen, lymph nodes and PBL of single individuals and to monitor the extent of T cell triggering. Studies have been performed with tissues either removed from infected monkeys or with normal human or monkey thymuses or spleens cultured as fragments in vitro. (I) Analysis of peripheral lymphoid organs from PBj infected rhesus and pigtailed monkeys indicates that despite the absence of circulating lymphocytes, activation in lymph nodes in contrast to that seen in spleen, can be quite vigorous. Proliferative potential (scored as stimulation indices) in mesenteric LN, however, differs from that in the distal axiallary nodes. (II) Examination of the susceptibility to infection of lymphoid organs has been studied by establishing in vitro fragment cultures of normal monkey and human thymus and spleen which are then infected with SIV and HIV respectively. Since lymphocytes in these tissues are 100 times more concentrated than in PBL, more efficient transmission of virus is expected. In agreement with previous reports using PBL, these results demonstrate that depending on the viral isolate, a loss of CD45RAlo, CD45RO+, CD44+, and CD4+ memory cells, in addition to CD45RAhi, CD45RO-activated T cells can occur within 11 days after infection. In contrast, CD45RAmed, CD45RO-, and CD44lo naive resting cells remain in the fragments. However, in studies with PBL from rhesus monkeys infected with the less cytopathic E11S virus or those rhesus that have survived PBj infection, modulation of CD45RAmed to CD45RAhi expression can be demonstrated. Indeed, this skewing, which leads to a change in the ratio of resting to activated CD45RA+ cells appears in most cases to be an indicator of active virus infection. Alterations in CD45 expression resulting from binding of inactivated virus to T cell CD4 in these cultures will also be discussed.
Keywords: Animal Antibodies, Monoclonal/IMMUNOLOGY Antigens, CD/*IMMUNOLOGY Biological Markers Comparative Study Cytopathogenic Effect, Viral Human HIV/GROWTH & DEVELOPMENT/IMMUNOLOGY HIV Infections/*IMMUNOLOGY Lymphocyte Transformation Macaca mulatta Phenotype Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Spleen/IMMUNOLOGY/*MICROBIOLOGY *SIV/GROWTH & DEVELOPMENT/IMMUNOLOGY T-Lymphocytes/IMMUNOLOGY/MICROBIOLOGY Virus Replication ABSTRACTKWDanimalantibodies,monoclonal/immunologyantigens,cd/KWDimmunologybiologicalmarkerscomparativestudycytopathogeniceffect,viralhumanhiv/growth&development/immunologyhivinfections/KWDimmunologylymphocytetransformationmacacamulattaphenotypesimianacquiredimmunodeficiencysyndrome/KWDimmunologyspleen/immunology/KWDmicrobiologyKWDsiv/growth&development/immunologyt-lymphocytes/immunology/microbiologyvirusreplicationabstract
910730
M9170966

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .